Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

Published:2021-05 Issue:5 Volume:9 Page:511-521
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Soin Arvinder S,Kumar Kuldeep,Choudhary Narendra S,Sharma Pooja,Mehta Yatin,Kataria Sushila,Govil Deepak,Deswal Vikas,Chaudhry Dhruva,Singh Pawan Kumar,Gupta Ashish,Agarwal Vikas,Kumar Suresh,Sangle Shashikala A,Chawla Rajesh,Narreddy Suneetha,Pandit Rahul,Mishra Vipul,Goel Manoj,Ramanan Athimalaipet V

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference22 articles.

1. Dexamethasone in hospitalized patients with Covid-19—preliminary report;Horby;N Engl J Med,2020

2. Remdesivir for the treatment of Covid-19—final report;Beigel;N Engl J Med,2020

3. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review;Wiersinga;JAMA,2020

4. Complex immune dysregulation in COVID-19 patients with severe respiratory failure;Giamarellos-Bourboulis;Cell Host Microbe,2020

5. Clinical characteristics of coronavirus disease 2019 in China;Guan;N Engl J Med,2020

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta-analysis;IJC Heart & Vasculature;2024-10

2. Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab;Infection;2024-08-29

3. Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study;BMC Infectious Diseases;2024-08-01

4. Infection and chronic disease activate a systemic brain-muscle signaling axis;Science Immunology;2024-07-12

5. Pharmacological validation of a novel exopolysaccharide from Streptomyces sp. 139 to effectively inhibit cytokine storms;Heliyon;2024-07